Rising Cancer Prevalence Driving Growth In The Market Driver: Leading Transformation in the Minimal Residual Disease Market in 2025

What combination of drivers is leading to accelerated growth in the minimal residual disease market?
The increasing prevalence of cancer is expected to drive the growth of the minimal residual disease (MRD) market in the future. Cancer refers to a group of diseases characterized by uncontrolled cell growth and spread. The rising prevalence of cancer is attributed to factors such as aging populations, environmental carcinogens, unhealthy lifestyles, and genetic factors. As cancer cases increase, the demand for precise MRD testing to detect residual cancer cells rises, allowing for early intervention and personalized treatment plans that improve relapse prediction and patient outcomes. For example, in May 2024, the National Cancer Institute (NCI) reported that in 2022, nearly 20 million new cancer cases and 9.7 million cancer-related deaths occurred globally, with projections for 2040 estimating 29.9 million new cases and 15.3 million cancer-related deaths. As such, the increasing prevalence of cancer is fueling the growth of the minimal residual disease market.

Get Your Minimal Residual Disease Market Report Here:
https://www.thebusinessresearchcompany.com/report/minimal-residual-disease-global-market-report

What is the projected compound annual growth rate (CAGR) of the minimal residual disease market from 2025 to 2034, and what factors influence it?
The minimal residual disease (MRD) market has expanded rapidly, increasing from $1.78 billion in 2024 to $2.01 billion in 2025 at a CAGR of 12.9%. Growth drivers include a rising number of cancer patients, increased research and development spending, improved healthcare affordability, a growing prevalence of blood cancer, and greater public awareness.

The minimal residual disease (MRD) market is set for rapid expansion, reaching $3.22 billion by 2029 at a CAGR of 12.5%. Factors driving this growth include a rising number of cancer cases, increasing government awareness programs, enhanced healthcare affordability, growing disposable income in emerging economies, and government efforts to raise awareness about MRD. Major trends anticipated in this sector include advancements in next-generation sequencing (NGS), standardization of MRD testing methods, the rise of personalized MRD monitoring, progress in liquid biopsy technology, and the development of MRD-targeted therapies.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21224&type=smp

How are the latest trends influencing the growth of the minimal residual disease market?
In the minimal residual disease (MRD) market, companies are focusing on advanced in vitro diagnostic (IVD) test services to provide personalized therapy options and improve patient outcomes. These tests help detect residual cancer cells after treatment, predict relapse, and optimize therapy. For example, in December 2022, Adaptive Biotechnologies Corporation, a US-based biotechnology company, launched the clonoSEQ Assay, which detects MRD in patients with diffuse large B-cell lymphoma (DLBCL). This test analyzes circulating tumor DNA (ctDNA) in blood samples, providing a highly sensitive, non-invasive method for monitoring cancer progression and early relapse detection. It is the first MRD test for DLBCL to receive Medicare coverage, ensuring broad accessibility for patients.

What are the major segments of the minimal residual disease market and their role in driving growth?
The minimal residual disease market covered in this report is segmented -

1) By Detection Target: Lymphoma, Leukemia, Solid Tumors, Other Detection Targets
2) By Test Technique: Flow Cytometry, Polymerase Chain Reaction (PCR), Next Generation Sequencing (NGS), Other Test Techniques
3) By End-User: Banking, Financial Services, And Insurance (BFSI), Retail And E-Commerce, Hospitals, Diagnostic Laboratories, Research Institutions

Subsegments:
1) By Lymphoma: Hodgkin Lymphoma, Non-Hodgkin Lymphoma
2) By Leukemia: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia
3) By Solid Tumors: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer
4) By Other Detection Targets: Multiple Myeloma, Neuroblastoma, Sarcomas

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21224

Which regions are key players in the growth of the minimal residual disease market?
North America was the largest region in the minimal residual disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the minimal residual disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Who are the key firms paving the way for growth in the minimal residual disease market?
Major companies operating in the minimal residual disease market are Thermo Fisher Scientific Inc., Amgen Inc., Laboratory Corporation of America Holdings (LabCorp), Quest Diagnostics Incorporated, Agilent Technologies Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., Qiagen N.V., Exact Sciences Corporation, Kite Pharma Inc., Natera Inc., Foundation Medicine Inc., NeoGenomics Inc., Guardant Health Inc., Grail LLC, Tempus AI Inc., Veracyte Inc., Adaptive Biotechnologies Corporation, Invivoscribe Inc., Mission Bio Inc., ArcherDx Inc.

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/sample.aspx?id=21224&type=smp

What Is Covered In The Minimal Residual Disease Global Market Report?

•Market Size Forecast: Examine the minimal residual disease market size across key regions, countries, product categories, and applications.
•Segmentation Insights: Identify and classify subsegments within the minimal residual disease market for a structured understanding.
•Key Players Overview: Analyze major players in the minimal residual disease market, including their market value, share, and competitive positioning.
•Growth Trends Exploration: Assess individual growth patterns and future opportunities in the minimal residual disease market.
•Segment Contributions: Evaluate how different segments drive overall growth in the minimal residual disease market.
•Growth Factors: Highlight key drivers and opportunities influencing the expansion of the minimal residual disease market.
•Industry Challenges: Identify potential risks and obstacles affecting the minimal residual disease market.
•Competitive Landscape: Review strategic developments in the minimal residual disease market, including expansions, agreements, and new product launches.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.